HIV Infection clinical trials
80 active trials name this biomarker in their eligibility criteria. Describe your situation to see which ones you may be eligible for.
- A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
- Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis
- Shared Decision Making to Treat Or Prevent (STOP) HIV in Criminal Legal Involved Populations (R33)
- A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
- A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
- Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
- Two-fraction HDR Monotherapy for Localized Prostate Cancer
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
- Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
- HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia
- HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer
- Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV
- A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
- Trial of Ixazomib for Kaposi Sarcoma
- External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
- Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
- Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)
- Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
- Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
- Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
- A Study to Improve Skeletal Muscle in Veterans With HIV
- A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
- Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
- A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV
- A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
- Inflammation and Depression in People With HIV
- Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use
- Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
- Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
- Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
- Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
- Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
- SMP-3124LP in Adults With Advanced Solid Tumors
- Auto Stem Cell Transplant for Lymphoma Patients
- Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
- Comprehensive HIV and Harm Prevention Via Telehealth
- Improving Coronary Vascular Health in Women
- Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
- PET Imaging and Lymph Node Assessment of IRIS in People With AIDS
- Observational PIC Destination Cohort
- Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors
- Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
- Skeletal Muscle Energetics and Fatiguability in Older Individuals
- Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
- Feasibility of HPV Testing With Mail-delivered Sample Collection Kits
- People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
- The DC Cohort Longitudinal HIV Status Neutral Study
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “HIV Infection” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.